Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Robert M Burkes & Ralph J Panos. (2020) Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. Journal of Experimental Pharmacology 12, pages 589-602.
Read now
Read now
Chenxi Li, Wenke Cheng, Jin Guo & Wei Guan. (2019) Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 799-808.
Read now
Read now
Timothy E Albertson, Willis S Bowman, Richart W Harper, Regina M Godbout & Susan Murin. (2019) Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1251-1265.
Read now
Read now
Antonio Molino, Giovanna Calabrese & Mauro Maniscalco. (2018) Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol. Patient Preference and Adherence 12, pages 993-1001.
Read now
Read now
Mohamed Ismail Abdul Aziz, Ling Eng Tan, David Bin-Chia Wu, Fiona Pearce, Gerald Seng Wee Chua, Liang Lin, Ping-Tee Tan & Kwong Ng. (2018) Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3203-3231.
Read now
Read now
Paola Rogliani, Maria Gabriella Matera, Josuel Ora, Mario Cazzola & Luigino Calzetta. (2017) The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 3469-3485.
Read now
Read now
Nicola A Hanania, Suzanne C. Lareau & Barbara P. Yawn. (2017) Safety of inhaled long-acting anti-muscarinic agents in COPD. Postgraduate Medicine 129:5, pages 500-512.
Read now
Read now
Articles from other publishers (19)
Mingjin Yang, Yishi Li, Youfan Jiang, Shuliang Guo, Jian-Qing He & Don D. Sin. (2023) Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. European Respiratory Journal 61:2, pages 2200302.
Crossref
Crossref
Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Vanita Tongbram, Mia Malmenäs, Jatin Agarwal, Maria Nassim, Marija Živković-Gojović, Yunrong Shen, Xinzhe Dong, Maria Duarte, Chris Compton, Claus F. Vogelmeier & David M. G. Halpin. (2022) Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Advances in Therapy 39:11, pages 4961-5010.
Crossref
Crossref
Yinhua Gong, Chen Lin, Yifeng Jin & Rong Chen. (2022) The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal 2022, pages 1-12.
Crossref
Crossref
Yiwen Gong, Yinghua Lv, Hongxia Liu, Qingshan Zheng & Lujin Li. (2022) Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD. Therapeutic Advances in Respiratory Disease 16, pages 175346662110660.
Crossref
Crossref
Shih-Lung Cheng. (2021) Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment. Journal of Clinical Medicine 10:12, pages 2649.
Crossref
Crossref
Shannon M. Nugent, Sara E. Golden, Elizabeth R. Hooker, Donald R. Sullivan, Charles R. ThomasJr.Jr., Mark E. Deffebach, Mithran S. Sukumar, Paul H. Schipper, Brandon H. Tieu, Drew Moghanaki, Juan Wisnivesky, Pamela Samson, Clifford Robinson & Christopher G. Slatore. (2020) Longitudinal Health-related Quality of Life among Individuals Considering Treatment for Stage I Non–Small-Cell Lung Cancer. Annals of the American Thoracic Society 17:8, pages 988-997.
Crossref
Crossref
Paola Rogliani, Maria Gabriella Matera, Beatrice Ludovica Ritondo, Ilaria De Guido, Ermanno Puxeddu, Mario Cazzola & Luigino Calzetta. (2019) Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulmonary Pharmacology & Therapeutics 59, pages 101841.
Crossref
Crossref
Jinchun Wu, Yi Ye, Chenxi Li, Wenqin Zhou & Rong Chang. (2019) Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD. Journal of Cardiovascular Pharmacology 74:3, pages 255-265.
Crossref
Crossref
Riju Ray, Lee Tombs, Ian Naya, Chris Compton, David A. Lipson & Isabelle Boucot. (2019) Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials. Pulmonary Pharmacology & Therapeutics 57, pages 101802.
Crossref
Crossref
Usman Maqsood, Terence N Ho, Karen Palmer, Fiona JR Eccles, Mohammed Munavvar, Ran Wang, Iain Crossingham & David JW Evans. (2019) Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
Mohd Kashif Siddiqui, Pragya Shukla, Martin Jenkins, Mario Ouwens, Deniz Guranlioglu, Patrick Darken & Mousumi Biswas. (2019)
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
2
-agonist fixed-dose combinations in COPD
. Therapeutic Advances in Respiratory Disease 13, pages 175346661989450.
Crossref
Crossref
Ami R. Buikema, Lee Brekke, Amy Anderson, Eleena Koep, Damon Van Voorhis, Lucie Sharpsten, Beth Hahn, Riju Ray & Richard H. Stanford. (2018) The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models. Multidisciplinary Respiratory Medicine 13:1.
Crossref
Crossref
M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, L. A. Vallejo-Aparicio, I. P. Naya, Y. Asukai, B. Alcázar-Navarrete, M. Miravitlles, F. García-Río & N. A. Risebrough. (2018) Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respiratory Research 19:1.
Crossref
Crossref
Riju Ray, Lee Tombs, Michael J. Asmus, Isabelle Boucot, David A. Lipson, Chris Compton & Ian Naya. (2018) Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials. Drugs & Aging 35:7, pages 637-647.
Crossref
Crossref
Steven D. Deas & Nikhil Huprikar. (2018) Dual bronchodilator therapy for chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 24:2, pages 130-137.
Crossref
Crossref
Marc Miravitlles, Gerard Urrutia, Alexander G. Mathioudakis & Julio Ancochea. (2017) Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respiratory Research 18:1.
Crossref
Crossref
Linda M. Nelsen, Margaret Vernon, Hector Ortega, Sarah M. Cockle, Steven W. Yancey, Guy Brusselle, Frank C. Albers & Paul W. Jones. (2017) Evaluation of the psychometric properties of the St George's Respiratory Questionnaire in patients with severe asthma. Respiratory Medicine 128, pages 42-49.
Crossref
Crossref
Han Ni, Aung Htet & Soe Moe. (2017) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2017:6.
Crossref
Crossref
Geoffrey L Chupp, Eric S Bradford, Frank C Albers, Daniel J Bratton, Jie Wang-Jairaj, Linda M Nelsen, Jennifer L Trevor, Antoine Magnan & Anneke ten Brinke. (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. The Lancet Respiratory Medicine 5:5, pages 390-400.
Crossref
Crossref